Encision today announced financial results for its fiscal 2018 third quarter that ended December 31, 2017.
|
|
| [05-February-2018] |
|
BOULDER, Colo., Feb. 5, 2018 /PRNewswire/ -- Encision, Inc. (OTC:ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2018 third quarter that ended December 31, 2017. The Company posted quarterly net revenue of $2.19 million for a quarterly net income of $56 thousand, or $0.01 per diluted share. These results compare to net revenue of $2.23 million for a quarterly net loss of $274 thousand, or $(0.03) per diluted share, in the year-ago quarter. Net revenue for the current quarter included net revenue of $95 thousand from an order for non-AEM product. Gross margin on net revenue was 56% in the fiscal 2018 third quarter and 48% in the fiscal 2017 third quarter. Gross margin on net revenue was higher in the current quarter as a result of product mix. Gross margin on net revenue was lowered further in last year's third quarter by higher slow moving and obsolete inventory costs and applying overhead costs to faster turnover inventory. The Company posted nine months net revenue of $6.7 million for a nine months net income of $354 thousand, or $0.03 per diluted share. These results compare to net revenue of $6.66 million for a nine months net loss of $612 thousand, or $(0.06) per diluted share, in the year-ago nine months. Net revenue for the current nine months included net revenue of $424 thousand from an order for non-AEM product. Gross margin on net revenue was 57% in the fiscal 2018 nine months and 49% in the fiscal 2017 nine months. Gross margin on net revenue was higher in the current nine months as a result of product mix and lower costs in manufacturing operations. Gross margin on net revenue was lowered further in the fiscal 2017 nine months by higher slow moving and obsolete inventory costs and applying overhead costs to faster turnover inventory. Net cash of $494 thousand was generated by operating activities in the current nine months compared to no cash generated by operating activities in last year's nine months. There was no income tax effect in the third quarter results as a result of the U.S. corporate tax reform enacted in December. "We are pleased to deliver another profitable quarter and to drive gross margin," said Greg Trudel, President and CEO. "Our increased cash flow and profitability is enabling us to reinvest into our success. We have held true to our strategy of driving operational excellence while bolstering our portfolio and channel with new products and clinical evidence and it is proving effective. In particular, we are adding direct sales representation in opportune areas and are accelerating a number of new product development projects. These moves promise to drive top line growth and to leverage our operational efficiencies for continued profitability." Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2017 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise. CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com Encision Inc.
Unaudited Condensed Statements of Operations
(in thousands, except per share information)
Three Months Ended Nine Months Ended
------------------ -----------------
December 31, December 31, December 31, December 31,
2017 2016 2017 2016
---- ---- ---- ----
Net revenue $2,190 $2,230 $6,716 $6,658
Cost of revenue 956 1,166 2,880 3,394
Gross profit 1,234 1,064 3,836 3,264
----- ----- ----- -----
Operating expenses:
Sales and marketing 570 639 1,745 1,882
General and
administrative 369 383 1,058 1,087
Research and
development 224 300 635 881
--- --- --- ---
Total operating
expenses 1,163 1,322 3,438 3,850
----- ----- ----- -----
Operating income
(loss) 71 (258) 398 (586)
Interest expense
and other income
(expense), net (15) (16) (44) (26)
--- --- --- ---
Income (loss)
before provision
for income taxes 56 (274) 354 (612)
Provision for
income taxes -- -- -- --
--- --- --- ---
Net income (loss) $56 $(274) $354 $(612)
=== ===== ==== =====
Net income (loss)
per share-basic $0.01 $(0.03) $0.03 $(0.06)
Net income (loss)
per share-diluted $0.01 $(0.03) $0.03 $(0.06)
Weighted average
number of shares-
basic 10,683 10,678 10,683 10,675
Weighted average
number of shares-
diluted 10,708 10,678 10,702 10,675
Encision Inc.
Unaudited Condensed Balance Sheets
(in thousands)
December 31, March 31,
2017 2017
---- ----
ASSETS
Cash and cash equivalents $213 $45
Restricted cash 25 50
Accounts receivable, net 937 1,042
Inventories, net 1,247 1,129
Prepaid expenses 143 62
--- ---
Total current assets 2,565 2,328
----- -----
Equipment, net 377 468
Patents, net 269 254
Other assets 18 17
--- ---
Total assets $3,229 $3,067
------ ------
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable $522 $403
Accrued compensation 182 268
Other accrued liabilities 271 248
Line of credit -- 275
Deferred rent 30 30
Total current liabilities 1,005 1,224
Deferred rent 18 41
Total liabilities 1,023 1,265
Common stock and additional paid-in capital 23,802 23,752
Accumulated (deficit) (21,596) (21,950)
------- -------
Total shareholders' equity 2,206 1,802
----- -----
Total liabilities and shareholders' equity $3,229 $3,067
------ ------
Encision Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)
Nine Months Ended
-----------------
December 31, December 31,
2017 2016
Operating activities:
Net income (loss) $354 $(612)
Adjustments to reconcile net income (loss) to cash generated by (used in) operating activities:
Depreciation and amortization 154 168
Share-based compensation expense 49 52
(Recovery from) provision for doubtful accounts, net (19) 11
(Recovery from) inventory obsolescence, net (20) (240)
Changes in operating assets and liabilities:
Accounts receivable 123 (250)
Inventories (98) 835
Prepaid expenses and other assets (83) (46)
Accounts payable 119 153
Accrued compensation and other accrued liabilities (85) (71)
--- ---
Net cash generated by operating activities 494 --
--- ---
Investing activities:
Acquisition of property and equipment (41) (104)
Patent costs (35) (21)
--- ---
Net cash (used in) investing activities (76) (125)
--- ----
Financing activities:
Paydown of credit facility, net change (275) (104)
Change in restricted cash 25 --
Net cash (used in) financing activities (250) (104)
---- ----
Net increase (decrease) in cash and cash equivalents 168 (229)
Cash and cash equivalents, beginning of period 45 293
--- ---
Cash and cash equivalents, end of period $213 $64
==== ===
View original content:http://www.prnewswire.com/news-releases/encision-reports-third-quarter-fiscal-year-2018-results-300592297.html SOURCE Encision Inc. |
||
Company Codes: OTC-BB:ECIA, OTC-PINK:ECIA, OTC-QX:ECIA |
